www.bjcancer.com

## Corrigendum

Serum levels of IL-6 and TNF- $\alpha$  correlate with clinicopathological features and patient survival in patients with prostate cancer

## V Michalaki, K Syrigos, P Charles and J Waxman


British Journal of Cancer (2004) **91,** 1227. doi:10.1038/sj.bjc.6602115 www.bjcancer.com © 2004 Cancer Research UK

Correction to: British Journal of Cancer (2004) 90, 2312-2316. doi: 10.1038/sj.bjc.6601814


Due to an error, the second author's name was omitted from the above paper. The correct author listing is shown below:

V Michalaki, M Odontiadis, K Syrigos, P Charles and J Waxman

Also, in the same paper, part of the labelling in Figures 1 and 2 is incorrect. The correct figures are reproduced below:



**Figure 1** Disease-specific survival in patients with localised prostate cancer, stratified into groups above or below the cutoff IL-6 level of  $2.1\,\mathrm{pg\,ml}^{-1}$ .



**Figure 2** Disease-specific survival in patients with localised prostate cancer, stratified into groups above or below the cutoff TNF- $\alpha$  level of  $1.9 \, \mathrm{pg} \, \mathrm{ml}^{-1}$ .